Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL)
Abstract
Methylthioadenosine phosphorylase (MTAP) is an important enzyme used for the salvage of adenine and methionine. Cells lacking this enzyme are expected to be sensitive to purine synthesis inhibitors and/or methionine starvation. We reported previously that the MTAP gene is deleted in adult T cell leukemia (ATL) cells. In the present study, we expanded our series and used a real-time quantitative PCR assay for accurate diagnosis of the deletion and nine of 65 primary ATL samples (13.8%) were MTAP negative. In spite of this low incidence, ATL cells showed significantly higher sensitivity to L-alanosine, an inhibitor of de novo adenosine monophosphate (AMP) synthesis, than normal lymphocytes, suggesting that the MTAP gene is inactivated not only by deletion but also by other mechanisms. Indeed, a real-time quantitative RT-PCR assay disclosed that primary ATL cells had significantly lower MTAP mRNA expression than normal lymphocytes. Since MTAP-negative ATL cell lines also showed much higher sensitivity to L-alanosine than MTAP-positive ATL cell lines, we used these cell lines to investigate whether it is possible to develop selective therapy targeting MTAP deficiency. A substrate of MTAP, methylthioadenosine (MTA) or its substitutes rescued concanavalin A (Con A)-activated normal lymphocyte proliferation from L-alanosine toxicity. All the compounds except 5'-deoxyadenosine, however, also caused the undesirable rescue of MTAP-negative ATL cell lines. 5'-Deoxyadenosine had the desired ability to rescue hematopoietic progenitor cells without rescuing ATL cell lines. These results support the rationale for a chemotherapy regimen of L-alanosine combined with 5'-deoxyadenosine rescue in MTAP-deficient ATL.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
L-alanosine inhibits conversion of inosine monophosphate to AMP and shows selective toxicity towards MTAP-null cancer cells.
“L-alanosine inhibits conversion of inosine monophosphate (IMP) to AMP, and shows selective toxicity towards MTAP-null cancer cells (Batova et al., 1999; Efferth et al., 2003; Harasawa et al., 2002), but was found to be clinically ineffective in patients with advanced MTAP-deficient tumors in a Phase II trial (Kindler et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Harasawa et al., 2002
Cites
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043 · see citing works
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · see citing works
Adult T-cell leukemia: clinical and hematologic features of 16 cases
Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., & Uchino, H. (1977) · Blood · doi:10.1182/blood.v50.3.481.bloodjournal503481 · Cited by 2,315 · see citing works
Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K. I., Shirakawa, S., & Miyoshi, I. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6476 · Cited by 2,252 · see citing works
Yoshida, M., Miyoshi, I., & Hinuma, Y. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2031 · Cited by 2,169 · see citing works
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950 · see citing works
Shimoyama, M., & members of The Lymphoma Study Group (1984–87) (1991) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08051.x · Cited by 1,608 · see citing works
LICHTMAN, M., Spivak, J. L., Boxer, L. A., Shattil, S. J., & HENDERSON, E. (2000) · Elsevier eBooks · doi:10.1016/b978-012448510-5/50140-0 · Cited by 392 · see citing works
Yamada, Y., Tomonaga, M., Fukuda, H., Hanada, S., Utsunomiya, A., Tara, M., Sano, M., Ikeda, S., Takatsuki, K., Kozuru, M., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02737.x · Cited by 354 · see citing works
Self-citationPhosphate-stimulated breakdown of 5′-methylthioadenosine by rat ventral prostate
Pegg, A. E., & Williams-Ashman, H. G. (1969) · Biochemical Journal · doi:10.1042/bj1150241 · Cited by 201 · see citing works
Yamada, Y. (1983) · Blood · doi:10.1182/blood.v61.1.192.192 · Cited by 166 · see citing works
Self-citationHomozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia
Hatta, Y., Hirama, T., Cw, M., Yamada, Y., Tomonaga, M., & Koeffler, H. (1995) · Blood · doi:10.1182/blood.v85.10.2699.bloodjournal85102699 · Cited by 161 · see citing works
Self-citationMethionine synthesis from 5’-methylthioadenosine in rat liver
Backlund, P. S., & Smith, R. A. (1982) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-06343-7_102 · Cited by 148 · see citing works
Fas Gene Mutation in the Progression of Adult T Cell Leukemia
Maeda, T., Yamada, Y., Moriuchi, R., Sugahara, K., Tsuruda, K., Joh, T., Atogami, S., Tsukasaki, K., Tomonaga, M., & Kamihira, S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1063 · Cited by 128 · see citing works
Self-citationKamatani, N., Nelson‐Rees, W. A., & Carson, D. A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.2.1219 · Cited by 127 · see citing works
Methionine synthesis from 5'-methylthioadenosine in rat liver.
Backlund, P. S., & Smith, R. A. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69835-2 · Cited by 126 · see citing works
Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia.
Yamada, Y., Hatta, Y., Murata, K., Sugawara, K., Ikeda, S., Masanobu, M. I. N. E., Maeda, T., Hirakata, Y., Kamihira, S., Tsukasaki, K., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1778 · Cited by 120 · see citing works
Self-citationNobori, T., Takabayashi, K., Tran, P. T., Orvis, L., Batova, A., Yu, A. L.-T., & Carson, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.6203 · Cited by 113 · see citing works
Self-citationChen, Z., Zhang, H., & Savarese, T. M. (1996) · PubMed · Cited by 90 · see citing works
Batova, A., Diccianni, M. B., Nobori, T., Vu, T., Yu, A. L.-T., Bridgeman, L. J., & Yu, A. L.-T. (1996) · Blood · doi:10.1182/blood.v88.8.3083.bloodjournal8883083 · Cited by 72 · see citing works
Self-citationAbsence of methylthioadenosine phosphorylase in human gliomas.
Nobori, T., Karras, J. G., Ragione, F. D., Waltz, T. A., Chen, P. P., & Carson, D. A. (1991) · PubMed · Cited by 71 · see citing works
Self-citationGiannakakou, P., Villalba, L., Li, H., Poruchynsky, M. S., & Fojo, T. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980105)75:1 · Cited by 60 · see citing works
Self-citationHori, H., Tran, P., Carrera, C. J., Hori, Y., Rosenbach, M., Carson, D. A., & Nobori, T. (1996) · PubMed · Cited by 58 · see citing works
Self-citationGonzález, M., Mateos, M., García‐Sánz, R., Balanzategui, A., López‐Pérez, R., Chillón, C., González, D., Alaejos, I., & Miguel, J. F. S. (2000) · Leukemia · doi:10.1038/sj.leu.2401617 · Cited by 57 · see citing works
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Fitchen, J. H., Riscoe, M. K., Dana, B. W., Lawrence, H. J., & Ferro, A. J. (1986) · PubMed · Cited by 56 · see citing works
Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers.
Nobori, T., Szinai, I., Amox, D. G., Parker, B. A., Olopade, O. I., Buchhagen, D. L., & Carson, D. A. (1993) · PubMed · Cited by 53 · see citing works
Self-citationBatova, A., Diccianni, M. B., Omura‐Minamisawa, M., Yu, A. L.-T., Carrera, C. J., Bridgeman, L. J., Kung, F., Pullen, J., Amylon, M. D., & Yu, A. L.-T. (1999) · PubMed · Cited by 50 · see citing works
Gale, G. R., & Schmidt, G. B. (1968) · Biochemical Pharmacology · doi:10.1016/0006-2952(68)90246-3 · Cited by 46 · see citing works
M'soka, T. J., Nishioka, J., Taga, A., Kato, K., Kawasaki, H., Yamada, Y., Yu, A. L.-T., Komada, Y., & Nobori, T. (2000) · Leukemia · doi:10.1038/sj.leu.2401771 · Cited by 45 · see citing works
Self-citationThe effect of surgery and chemotherapy on blood NK cell activity in patients with ovarian cancer
Łukomska, B., Olszewski, W. L., Engeset, A., & Kolstad, P. (1983) · Cancer · doi:10.1002/1097-0142(19830201)51:3 · Cited by 41 · see citing works
Tyagi, A. K., & Cooney, D. A. (1980) · PubMed · Cited by 41 · see citing works
IL-2-Dependent ATL cell lines with phenotypes differing from the original leukemia cells
Yamada, Y., Nagata, Y., Kamihira, S., Tagawa, M., Ichimaru, M., Tomonaga, M., & Shiku, H. (1991) · Leukemia Research · doi:10.1016/0145-2126(91)90031-n · Cited by 35 · see citing works
Self-citationChavez, M. L. (2000) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/57.2.119 · Cited by 27 · see citing works
Anandaraj, S., Jayaram, H. N., Cooney, D. A., Tyagi, A. K., Han, N. C., Thomas, J. H., Chitnis, M. P., & Montgomery, J. A. J. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90333-0 · Cited by 27 · see citing works
Yu, A. L.-T., Batova, A., Shao, L., Carrera, C. J., & Yu, A. L.-T. (1997) · PubMed · Cited by 27 · see citing works
Yamada, Y., Fujita, M., Suzuki, H., Atogami, S., Sohda, H., Murata, K., Tsukasaki, K., Momita, S., Kohno, T., Maeda, T., et al. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb05012.x · Cited by 26 · see citing works
Self-citationTyagi, A. K., & Cooney, D. A. (1984) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60265-3 · Cited by 25 · see citing works
Hata, T., Fujimoto, T., Tsushima, H., Murata, K., Tsukasaki, K., Atogami, S., Sohda, H., Honda, S., Masanobu, M. I. N. E., Yamada, Y., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401271 · Cited by 12 · see citing works
Self-citationThe treatment of acute leukemia with continuous infusion L-Alanosine
Weick, J. K., Tranum, B. L., & Morrison, F. S. (1983) · Investigational New Drugs · doi:10.1007/bf00208898 · Cited by 9 · see citing works
Phase I study of L-alanosine using a daily x 3 schedule.
Dosik, G. M., Stewart, D. E., Valdivieso, M., Burgess, M. A., & Bodey, G. P. (1982) · PubMed · Cited by 8 · see citing works
Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer.
Creagan, E. T., Schutt, A. J., Ingle, J. N., & O'Fallon, J. R. (1983) · PubMed · Cited by 8 · see citing works
Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
O'Connell, M. J., Rubin, J., Schutt, A. J., Moertel, C. G., & Kvols, L. K. (1983) · PubMed · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works
“L-alanosine inhibits conversion of inosine monophosphate (IMP) to AMP, and shows selective toxicity towards MTAP-null cancer cells (Batova et al., 1999; Efferth et al., 2003; Harasawa et al., 2002), but was found to be clinically ineffective in patients with advanced MTAP-deficient tumors in a Phase II trial (Kindler…”
BackgroundINK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442 · see citing works
Illei, P. B., Rusch, V. W., Zakowski, M. F., & Ladanyi, M. (2003) · PubMed · Cited by 309 · see citing works
Huang, H.-Y., Illei, P. B., Zhao, Z., Mazumdar, M., Huvos, A. G., Healey, J. H., Wexler, L. H., Gorlick, R. G., Meyers, P. A., & Ladanyi, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.081 · Cited by 247 · see citing works
Natural history of adult T-cell leukemia/lymphoma and approaches to therapy
Taylor, G. P., & Matsuoka, M. (2005) · Oncogene · doi:10.1038/sj.onc.1208979 · Cited by 220 · see citing works
“Nonleukaemic cells can, in vitro, be protected from this effect by simultaneous treatment with 50-deoxyadenosine (Harasawa et al., 2002).”
BackgroundTransition state analogs of 5′-methylthioadenosine nucleosidase disrupt quorum sensing
Gutierrez, J. A., Crowder, T., Rinaldo-Matthis, A., Ho, M.-C., Almo, S. C., & Schramm, V. L. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.153 · Cited by 164 · see citing works
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity
Bertino, J. R., Waud, W. R., Parker, W. B., & Lubin, M. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.7.14948 · Cited by 151 · see citing works
Hustinx, S. R., Leoni, L. M., Yeo, C. J., Brown, P. N., Goggins, M., Kern, S. E., Hruban, R. H., & Maitra, A. (2005) · Modern Pathology · doi:10.1038/modpathol.3800377 · Cited by 125 · see citing works
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
Đačić, S., Kothmaier, H. E., Land, S. R., Shuai, Y., Halbwedl, I., Morbini, P., Murer, B., Comin, C., Galateau-Sallé, F., Demirağ, F., et al. (2008) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-008-0689-3 · Cited by 116 · see citing works
Jimeno, A., & Hidalgo, M. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0005 · Cited by 92 · see citing works
“Novel chemotherapeutic strategies exploiting the selective loss of MTAP function in cancers have been proposed, using inhibitors of de novo AMP synthesis such as L-alanosine (79).”
MethodKindler, H. L., Burris, H. A., Sandler, A. B., & Oliff, I. A. (2009) · Investigational New Drugs · doi:10.1007/s10637-008-9160-1 · Cited by 79 · see citing works
“In addition, co-administration of an MTAP substrate as salvage therapy is another potential strategy for protecting normal cells and tissues from cytotoxic effects of L-alanosine, although development of an effective and safe salvage agent is still in preclinical study [13, 14, 26, 27].”
BackgroundWorsham, M. J., Chen, K. M., Tiwari, N., Pals, G., Schouten, J. P., Sethi, S. N., & Benninger, M. S. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.4.409 · Cited by 69 · see citing works
Su, C., Chang, Y., Chan, Y.-C., Lin, T., Huang, M., Yang, C., & Hsiao, M. (2014) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2014.04.017 · Cited by 66 · see citing works
Picomolar Inhibitors as Transition-State Probes of 5′-Methylthioadenosine Nucleosidases
Gutierrez, J. A., Luo, M., Singh, V., Li, L., Brown, R. L., Norris, G. E., Evans, G. B., Furneaux, R. H., Tyler, P. C., Painter, G. F., et al. (2007) · ACS Chemical Biology · doi:10.1021/cb700166z · Cited by 66 · see citing works
Borczuk, A., Taub, R. N., Hesdorffer, M. E., Hibshoosh, H. H., Chabot, J. A., Keohan, M. L., Alsberry, R., Alexis, D., & Powell, C. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1884 · Cited by 65 · see citing works
Concordant Loss of MTAP and p16/CDKN2A Expression in Gastroesophageal Carcinogenesis
Powell, E. L., Leoni, L. M., Canto, M. I., Forastiere, A. A., Iacobuzio–Donahue, C. A., Wang, J. S., Maitra, A., & Montgomery, E. A. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000170349.47680.e8 · Cited by 61 · see citing works
Molecular predictors of response to pembrolizumab in thymic carcinoma
He, Y., Ramesh, A., Gusev, Y., Bhuvaneshwar, K., & Giaccone, G. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100392 · Cited by 59 · see citing works
Molecular Characteristics of Pancreatic Ductal Adenocarcinoma
Ottenhof, N. A., de Wilde, R. F., Maitra, A., Hruban, R. H., & Offerhaus, G. J. A. (2011) · Pathology Research International · doi:10.4061/2011/620601 · Cited by 58 · see citing works
“MTAP might be a possible therapeutic target as approaches to selectively target cells with MTAP defects have already been developed [137, 138].”
Lupus autoimmunity altered by cellular methylation metabolism
Yang, M., Gee, A. J. P., Gee, R. J., Zurita‐Lopez, C. I., Khare, S., Clarke, S. G., & Mamula, M. J. (2012) · Autoimmunity · doi:10.3109/08916934.2012.732133 · Cited by 50 · see citing works
Transition-State Structure of Human 5‘-Methylthioadenosine Phosphorylase
Singh, V., & Schramm, V. L. (2006) · Journal of the American Chemical Society · doi:10.1021/ja065419p · Cited by 46 · see citing works
Commonly dysregulated genes in murine APL cells
Yuan, W., Payton, J. E., Holt, M. S., Link, D. C., Watson, M. A., DiPersio, J. F., & Ley, T. J. (2006) · Blood · doi:10.1182/blood-2006-07-036640 · Cited by 40 · see citing works
Watanabe, F., Takao, M., Inoue, K., Nishioka, J., Nobori, T., Shiraishi, T., 金田, 正., Sakai, T., Yada, I., & Shimpo, H. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.04.019 · Cited by 39 · see citing works
Self-citationHomozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers
Karikari, C. A., Mullendore, M. E., Eshleman, J. R., Argani, P., Leoni, L. M., Chattopadhyay, S., Hidalgo, M. M., & Maitra, A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0103 · Cited by 35 · see citing works
“L-Alanosine, the L-isomer of alanosine, is a potent inhibitor of the de novo pathway of AMP synthesis (4, 6, 14).”
BackgroundSingh, V., Luo, M., Brown, R. L., Norris, G. E., & Schramm, V. L. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0754204 · Cited by 33 · see citing works
Identification of gene expression profiles predicting tumor cell response to L-alanosine
Efferth, T., Gebhart, E., Ross, D. D., & Sauerbrey, A. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00341-1 · Cited by 29 · see citing works
MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer
Pulous, F. E., Steurer, B., Pun, F. W., Zhang, M., Ren, F., & Zhavoronkov, A. A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104189 · Cited by 22 · see citing works
Circadian pharmacology of l -alanosine (SDX-102) in mice
Li, X., Kanekal, S., Crépin, D., Guettier, C., Carrière, J., Elliott, G., & Lévi, F. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0332 · Cited by 18 · see citing works
An Improved Stereoselective Synthesis of L ‐Alanosine
Strazzolini, P., Dall’Arche, M. G., Zossi, M., & Pavsler, A. (2004) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200400508 · Cited by 17 · see citing works
Methylthioadenosine phosphorylase deficiency in Japanese osteosarcoma patients
Matsumine, A., Uchida, A., Nobori, T., Shiraishi, T., Nishioka, J., & Miyazaki, S. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.5.1069 · Cited by 15 · see citing works
Self-citationHe, H.-L., Lee, Y.-E., Shiue, Y., Lee, S., Chen, T., & Li, C. (2015) · Medicine · doi:10.1097/md.0000000000002271 · Cited by 14 · see citing works
HIV vector-mediated targeted suicide gene therapy for adult T-cell leukemia
Miyake, K., Inokuchi, K., Miyake, N., Dan, K., & Shimada, T. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303024 · Cited by 9 · see citing works
Manjunath, K., Jeyakanthan, J., & Sekar, K. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.06.006 · Cited by 7 · see citing works
Laskowska, J., Lewandowska‐Bieniek, J., Szczepanek, J., Styczyński, J., & Tretyn, A. (2016) · The Journal of Gene Medicine · doi:10.1002/jgm.2889 · Cited by 7 · see citing works
“However, a chemoselective treatment strategy may be complicated because of tumor heterogeneity [45,46].”
BackgroundGebhart, E., Liehr, T., Wolff, E., Wiltfang, J., Koscielny, S., & Ries, J. (2003) · Cytogenetic and Genome Research · doi:10.1159/000074164 · Cited by 7 · see citing works
“More recently its involvement in purine metabolism (Carrera et al., 1984; Olopade et al., 1992; Della Ragione et al., 1995, Chen et al., 1996) advanced it to a highly interesting target of therapeutic attempts (Efferth et al., 2002; Harasawa et al., 2002).”
BackgroundJassinskaja, M., Ghosh, S., Watral, J., Davoudi, M., Stern, M. C., Daher, U., Eldeeb, M., Zhang, Q., Bryder, D., & Hansson, J. (2024) · Leukemia · doi:10.1038/s41375-024-02235-5 · Cited by 6 · see citing works
Determination of derivatized l-alanosine in plasma by liquid chromatography-tandem mass spectrometry
Gantverg, A., Elliott, G., Pineault, J. M., & Demers, R. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.01.003 · Cited by 5 · see citing works
MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies
Subramaniam, B., Chong, W. C., Babaei, A., Bornhorst, M., Zhang, C., Packer, R. J., & Nazarian, J. (2025) · Cells · doi:10.3390/cells14241964 · Cited by 4 · see citing works
“The sensitivity of ALA on MTAP-deficient tumors was also apparent in adult T-cell leukemia (ALT) [136].”
Conde, L., Vilaseca, I., Alós, L., Bernal‐Sprekelsen, M. S., Cardesa, A., & Nadal, A. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04353.x · Cited by 4 · see citing works
“cells deprived of MTAP become dependent on de-novo adenosine synthesis and, consequently, become highly sensitive to in-vitro treatment with purine synthesis inhibitors.(8,14,15) MTAP gene deletions have been reported in a variety of cancers and cell lines,(6,16) ranging from 12% of adult T cell leukaemia(17) to 75% o…”
BackgroundTherapeutic Targeting of Methylthioadenosine Phosphorylase
(2016) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1322 · Cited by 3 · see citing works
Noë, M., Hackeng, W. M., de Leng, W. W. J., Vergeer, M., Vleggaar, F. P., Morsink, F. H. M., Wood, L. D., Hruban, R. H., Offerhaus, G. J. A., & Brosens, L. A. A. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001314 · Cited by 3 · see citing works
Biomarkers for pancreatic carcinogenesis
Hustinx, S. R. (2007) · Utrecht University Repository (Utrecht University)
Thermodynamics of transition state analogs
Schramm, V. L., & Paparella, A. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21848-4.00014-5
Neyaz, A., Shaker, N., Abdul-Baki, M.-N., Surakji, H., Rammal, R., Bedell, M., Baroudi, I., Mansour, A., Bellizzi, A. M., & Abukhiran, I. M. (2026) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001299
BindingDB (2011) · UC San Diego · doi:10.7270/q2qf8r7w
BindingDB (2011) · UC San Diego · doi:10.7270/q28c9tm9
- Authors
- Harasawa, H., Yamada, Y., Kudoh, M., Sugahara, K., Soda, H., Hirakata, Y., Sasaki, H., Ikeda, S., Matsuo, T., Tomonaga, M., Nobori, T., & Kamihira, S.
- Affiliations
- Nagasaki University (JP)
- Nagasaki University Hospital (JP)
- Sasebo City General Hospital (JP)
- Mie University (JP)
- Venue
- Leukemia
- Published
- 2002-08-30
- Volume
- 16
- Issue
- 9
- Pages
- 1799-1807
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2332501724
- Cited by
- 45
- References
- 42
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 1 · 2012: 2
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- adult T-cell leukemia/lymphoma, MTAP, MTAP deficiency, 5'-deoxyadenosine, purine synthesis inhibitors, salvage pathway, methylthioadenosine, hematopoietic progenitor cells, targeted chemotherapy
- MeSH terms
- Adenosine Monophosphate, Antibiotics, Antineoplastic, Cell Division, Colony-Forming Units Assay, Humans, Lymphocyte Activation, Purine-Nucleoside Phosphorylase, RNA, Messenger, RNA, Neoplasm, Thymidine, Blotting, Southern, Leukemia-Lymphoma, Adult T-Cell, Gene Deletion, DNA Primers, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
